ArticleOncotarget2018
Clonal heterogeneity of
Open access · diamondAbstract read
In one paragraph
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Day + 30 detection of minimal residual FLT3-ITD by high-sensitivity PCR-NGS predicts relapse risk and guides post-transplant maintenance in AML.BMC medicine · 2026Article
- Prognostic covariates associated with outcomes in patients with NPM1-mutated acute myeloid leukemia.The oncologist · 2025Article
- Article
- Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia.Blood advances · 2025Article
- Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection.OncoTargets and therapy · 2025Article
- Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity.Leukemia · 2024Article
- The Clinical Utility ofCurrent oncology (Toronto, Ont.) · 2023Article
- Gilteritinib: The Story of a Proceeding Success into Hard-to-TreatJournal of clinical medicine · 2023Review
- Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.International journal of molecular sciences · 2023Review
- Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r.BMC bioinformatics · 2022Article
- Article
- A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication.Diagnostic pathology · 2022Article
- Accurate Detection and Quantification of FLT3 Internal Tandem Duplications in Clinical Hybrid Capture Next-Generation Sequencing Data.The Journal of molecular diagnostics : JMD · 2021Article
- FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation.Molecular oncology · 2021Article
- Early T-cell precursor acute lymphoblastic leukemia and other subtypes: a retrospective case report from a single pediatric center in China.Journal of cancer research and clinical oncology · 2021Article
- Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms.The Journal of molecular diagnostics : JMD · 2020Article
- Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities.Frontiers in genetics · 2020Review
- Article
- Clinical implications of recurrent gene mutations in acute myeloid leukemia.Experimental hematology & oncology · 2020Review
- Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 9 institutions in 2 countries.
Katrin SchranzExperimental Leukemia and Lymphoma Research, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Max HubmannLaboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Egor HarinLaboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Sebastian VosbergExperimental Leukemia and Lymphoma Research, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Tobias HeroldLaboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Klaus H MetzelerExperimental Leukemia and Lymphoma Research, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Maja Rothenberg-ThurleyLaboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Hanna JankeLaboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Kathrin BräundlLaboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Bianka KsienzykLaboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Aarif M N BatchaDepartment of Medical Data Processing, Biometrie and Epidemiology, LMU Munich, Munich, Germany.
Sebastian SchaafDepartment of Medical Data Processing, Biometrie and Epidemiology, LMU Munich, Munich, Germany.
Stephanie SchneiderLaboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Stefan K BohlanderLeukaemia and Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Dennis GörlichInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
Wolfgang E BerdelDepartment of Medicine A, Hematology and Oncology, University of Münster, Münster, Germany.
Bernhard J WörmannDivision of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany.
Jan BraessDepartment of Hematology and Oncology, Barmherzige Brüder Hospital, Regensburg, Germany.
Stefan KrebsLaboratory for Functional Genome Analysis, Gene Center, LMU Munich, Munich, Germany.
Wolfgang HiddemannExperimental Leukemia and Lymphoma Research, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Ulrich MansmannDepartment of Medical Data Processing, Biometrie and Epidemiology, LMU Munich, Munich, Germany.
Karsten SpiekermannExperimental Leukemia and Lymphoma Research, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Philipp A GreifExperimental Leukemia and Lymphoma Research, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Ludwig-Maximilians-Universität München · DEGerman Cancer Research Center · DELMU Klinikum · DEMunich Leukemia Laboratory (Germany) · DEUniversity of Münster · DECharité - Universitätsmedizin Berlin · DEHeidelberg University · DEKrankenhaus Barmherzige Brüder · DEUniversity of Auckland · NZ
Funding
No grant is acknowledged in the PubMed record.
Abstract
In acute myeloid leukemia (AML), internal tandem duplications (ITDs) of
Indexed as
acute myeloid leukemia (AML)fms-related tyrosine kinase 3 (FLT3)fragment analysisiternal tandem duplication (ITD)next generation sequencing (NGS)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.